New antidiabetic agents enable many patients with type 2 diabetes mellitus (T2DM) to achieve target HbA1clevels. However, a range of factors can interfere with the ability of some patients to reach metabolic targets. This Review discusses the current therapies for patients with T2DM and assesses the relative benefits and risks of surgical treatment of overweight and obese patients with T2DM.
